{
    "Trade/Device Name(s)": [
        "Liquichek Tumor Marker Control"
    ],
    "Submitter Information": "Bio-Rad Laboratories",
    "510(k) Number": "K141073",
    "Predicate Device Reference 510(k) Number(s)": [
        "K071675"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "JJY"
    ],
    "Summary Letter Date": "June 23, 2014",
    "Summary Letter Received Date": "April 25, 2014",
    "Submission Date": "April 23, 2014",
    "Regulation Number(s)": [
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Quality control material (assayed and unassayed)"
    ],
    "Analyte Class(es)": [
        "cancer molecular",
        "chemistry"
    ],
    "Analyte(s)": [
        "Alpha Fetoprotein (AFP)",
        "Beta-2-Microglobulin (B2-M)",
        "CA 15-3",
        "CA 19-9",
        "CA 125",
        "Carcinoembryonic Antigen (CEA)",
        "Ferritin",
        "Human Chorionic Gonadotropin (hCG)",
        "Prolactin",
        "Prostate Specific Antigen, Total (Total PSA)",
        "Prostate Specific Antigen, Free (Free PSA)"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [
        "Siemens Dimension Vista Vials"
    ],
    "Instrument(s)/Platform(s)": [
        "Siemens Dimension Vista Systems"
    ],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [],
    "Submission Type(s)": [
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Bio-Rad Liquichek Tumor Marker Control, a multi-analyte assayed quality control serum for cancer and related biomarkers.",
    "Indications for Use Summary": "Intended for use as an assayed quality control serum to monitor the precision of laboratory testing procedures for listed tumor marker analytes.",
    "fda_folder": "Clinical Chemistry"
}